

POLICY NAME	Tavneos (avacopan)	POLICY #	3256P
--------------------	--------------------	-----------------	--------------

Criteria

Coverage Criteria

- ☐ **1.1** Diagnosis of one of the following types of severe active Anti-Neutrophil Cytoplasmic Autoantibody (ANCA)-associated vasculitis:
 - Granulomatosis with polyangiitis (Wegener's granulomatosis)
 - Microscopic polyangiitis
- ☐ **1.2** Diagnosis confirmed by one of the following:
 - ANCA test positive for proteinase 3 (PR3) antigen
 - ANCA test positive for myeloperoxidase (MPO) antigen
 - Tissue biopsy
- ☐ **1.3** Documentation to support Birmingham Vasculitis Activity Score (BVAS) containing at least 1 major item, 3 non-major items, or 2 renal items of proteinuria and hematuria
- ☐ **1.4** Age 18 years or older
- ☐ **1.5** Prescribed by or in consultation with a rheumatologist (musculoskeletal doctor), nephrologist (kidney doctor), or immunologist (immune system doctor)
- ☐ **1.6** Patient is currently receiving standard therapy with cyclophosphamide or rituximab
- ☐ **1.7** Patient is currently on glucocorticoids or has a contraindication or intolerance

Exclusion Criteria – Any of the following prevents coverage

- ☐ **2.1** Currently on dialysis or previous kidney transplant
- ☐ **2.2** Diagnosis of Eosinophilic Granulomatosis with Polyangiitis (EGPA)